


Lumigenic Therapeutics Revenue
Biotechnology Research • Nashville, Tennessee, United States • 1-10 Employees
$
Lumigenic Therapeutics revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Key Contact at Lumigenic Therapeutics
Darsh Shrivastava
Co-Founder and Co-CEO
Company overview
| Headquarters | Nashville, Tennessee, United States |
| NAICS | 541714 |
| Founded | 2025 |
| Employees | 1-10 |
About Lumigenic Therapeutics
- Lumigenic Protein Services (releasing very soon) - Lumigenic System (work in progress)
Employees by Management Level
Total employees: 1-10
Seniority
Employees
C-Suite
Employees by Department
Lumigenic Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
HR
1
Funding Data
Lumigenic Therapeutics has never raised funding before.
Frequently asked questions
What is the address of Lumigenic Therapeutics?
Lumigenic Therapeutics is located in Nashville, Tennessee, US.
What are the revenues of Lumigenic Therapeutics?
Lumigenic Therapeutics generates an estimated annual revenue of $256,665. This revenue figure reflects the company's market position and business performance in its industry.
What is the valuation of Lumigenic Therapeutics?
Lumigenic Therapeutics has an estimated valuation of $821,328. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
When was Lumigenic Therapeutics founded?
Lumigenic Therapeutics was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.
How many employees does Lumigenic Therapeutics have?
Lumigenic Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users



